Search - tctmd.com

Displaying 581 - 595 of 595

Sort: Relevancy | Date

News Daily News

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Michael O'Riordan

March 02, 2016

News Daily News

NEJM支持 Robert Califf担任FDA局长

L.A. McKeown

October 30, 2015

News Daily News

NEJM Endorses Robert Califf for FDA Commissioner

L.A. McKeown

October 30, 2015

News Daily News

NEJM Apoya a Robert Califf como Comisionado de la FDA

L.A. McKeown

October 30, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Daily News

美国的女性介入医生依然很罕见

Yael L. Maxwell

August 21, 2015

News Daily News

Las Mujeres Intervencionistas Siguen Siendo una Rareza en EE.UU.

Yael L. Maxwell

August 21, 2015

News Daily News

Female Interventionalists Remain a Rarity in the United States

Yael L. Maxwell

August 21, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Daily News

MI患者的低试验参与率引起了对适用性的质疑

Todd Neale

September 02, 2014

News Daily News

Low Trial Participation Rate of MI Patients Raises Questions of Applicability

Todd Neale

September 02, 2014

News Daily News

El Bajo Índice de Participación del Ensayo de Pacientes IM Plantea Dudas de Aplicabilidad

Todd Neale

September 02, 2014

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

News Daily News

Low US Participation in NIH-Sponsored CVD Trials Cause for Concern

Jason Kahn

August 01, 2011

Advertisement

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

NEJM支持 Robert Califf担任FDA局长

NEJM Endorses Robert Califf for FDA Commissioner

NEJM Apoya a Robert Califf como Comisionado de la FDA

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

美国的女性介入医生依然很罕见

Las Mujeres Intervencionistas Siguen Siendo una Rareza en EE.UU.

Female Interventionalists Remain a Rarity in the United States

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

MI患者的低试验参与率引起了对适用性的质疑

Low Trial Participation Rate of MI Patients Raises Questions of Applicability

El Bajo Índice de Participación del Ensayo de Pacientes IM Plantea Dudas de Aplicabilidad

Innovation in Intervention: Perspectives from Industry

Low US Participation in NIH-Sponsored CVD Trials Cause for Concern

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content